These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33236520)

  • 1. Dynamic ordering design for dose finding in drug-combination trials.
    Zhang T; Yang Z; Yin G
    Pharm Stat; 2021 Mar; 20(2):348-361. PubMed ID: 33236520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials.
    Zhang L; Yuan Y
    Stat Med; 2016 Nov; 35(27):4924-4936. PubMed ID: 27580928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
    Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
    Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A nonparametric Bayesian method for dose finding in drug combinations cancer trials.
    Razaee ZS; Cook-Wiens G; Tighiouart M
    Stat Med; 2022 Mar; 41(6):1059-1080. PubMed ID: 35075652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Escalation with overdose control for phase I drug-combination trials.
    Shi Y; Yin G
    Stat Med; 2013 Nov; 32(25):4400-12. PubMed ID: 23630103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering.
    Guo B; Li Y
    Stat Med; 2015 Feb; 34(5):859-75. PubMed ID: 25413162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-finding design for multi-drug combinations.
    Wages NA; Conaway MR; O'Quigley J
    Clin Trials; 2011 Aug; 8(4):380-9. PubMed ID: 21652689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Competing designs for drug combination in phase I dose-finding clinical trials.
    Riviere MK; Dubois F; Zohar S
    Stat Med; 2015 Jan; 34(1):1-12. PubMed ID: 24464821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian optimization design for finding a maximum tolerated dose combination in phase I clinical trials.
    Takahashi A; Suzuki T
    Int J Biostat; 2021 Apr; 18(1):39-56. PubMed ID: 33818029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial design for drug combinations with Bayesian model averaging.
    Jin IH; Huo L; Yin G; Yuan Y
    Pharm Stat; 2015; 14(2):108-19. PubMed ID: 25641851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bayesian optimal interval design for dose finding in drug-combination trials.
    Lin R; Yin G
    Stat Methods Med Res; 2017 Oct; 26(5):2155-2167. PubMed ID: 26178591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Keyboard design for phase I drug-combination trials.
    Pan H; Lin R; Zhou Y; Yuan Y
    Contemp Clin Trials; 2020 May; 92():105972. PubMed ID: 32151751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian optimization design for dose-finding based on toxicity and efficacy outcomes in phase I/II clinical trials.
    Takahashi A; Suzuki T
    Pharm Stat; 2021 May; 20(3):422-439. PubMed ID: 33258282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A benchmark for dose-finding studies with unknown ordering.
    Mozgunov P; Paoletti X; Jaki T
    Biostatistics; 2022 Jul; 23(3):721-737. PubMed ID: 33409536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bayesian adaptive linearization method for phase I drug combination trials with dimension reduction.
    Pan H; Cheng C; Yuan Y
    Pharm Stat; 2020 Sep; 19(5):561-582. PubMed ID: 32248647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A hybrid design for dose-finding oncology clinical trials.
    Liao JJZ; Zhou F; Zhou H; Petruzzelli L; Hou K; Asatiani E
    Int J Cancer; 2022 Nov; 151(9):1602-1610. PubMed ID: 35802470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A clinical phase I dose-finding design with adaptive shrinking boundaries for drug combination trials.
    Li Z; Xu Z; Zhang A; Qi G; Li Z
    BMC Med Res Methodol; 2023 Mar; 23(1):57. PubMed ID: 36864387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flexible use of copula-type model for dose-finding in drug combination clinical trials.
    Hashizume K; Tshuchida J; Sozu T
    Biometrics; 2022 Dec; 78(4):1651-1661. PubMed ID: 34181760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison Between Simultaneous and Sequential Utilization of Safety and Efficacy for Optimal Dose Determination in Bayesian Model-Assisted Designs.
    Li R; Takeda K; Rong A
    Ther Innov Regul Sci; 2023 Jul; 57(4):728-736. PubMed ID: 37087525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonparametric overdose control with late-onset toxicity in phase I clinical trials.
    Lin R; Yin G
    Biostatistics; 2017 Jan; 18(1):180-194. PubMed ID: 27549121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.